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Purpose of the study
Factors associated with CCR5 coreceptor usage are not yet
extensively evaluated; in some studies high CD4 and low
viremia have been considered predictive [1,2]. We evalu-
ated factors predicting the viral tropism in failing patients
with long exposure to HIV, screened for Maraviroc
Expanded Access Program (A4001050) at San Raffaele
Hospital.
Methods
Viral tropism was determined in 98/116 (84%) (Viro-
Logic PhenoSense assay). Viral tropism was classified as
R5, D/M or X4 for virus that used CCR5 coreceptor, CCR5
and CXCR4 coreceptors or CXCR4 coreceptor, respec-
tively. Variables evaluated for the association with the R5
virus (outcome variable) were: age, gender, CDC stage (C
vs. A and B), screening CD4 percentage, CD4+ cells, HIV-
1 plasma RNA level, nadir CD4+, risk factor (IVDU vs.
other), time since HIV infection. All these characteristics
were considered at univariable and multivariable analysis.
Logistic regression was applied at multivariable analysis.
Data were described as median (Q1–Q3) or frequency
(%), as appropriate.
Summary of results
56 (57.1%) patients had R5 virus, 40 (40.1%) had D/M
virus, two (4.1%) had X4 virus; only R5 and D/M groups
were considered for this analysis; 82 (85.4%) were males,
age 45.7 (42.6–50.8) years; 15 (19.5%) were IVDU, HIV
exposure 15.8 (12.7–18.7) years, 41 (43%) had a C CDC
stage. Screening characteristics were: CD4 240 cells/cmm
(133–364); CD4% 12.7(8.6–19.2); HIV-RNAlog10 cop-
ies/mL 4.31(3.82–4.94).
Female were more likely to have D/M virus [10/14 (71%)
vs. 30/82 (37%) ; p = 0.0195]. The D/M group had a sig-
nificantly lower screening CD4+ cells percentage than R5
group (11.0% (7.3–17.8) vs. 15.3% (9.4–20.6); p =
0.055). No other differences on the screening characteris-
tics were found in relation to coreceptor usage (age: p =
0.296; HIV-1 plasma RNA level: p = 0.855; nadir CD4+: p
= 0.070; CD4+: p = 0.079; CDC stage: p = 0.202; risk fac-
tor of HIV transmission: p = 0.574, HIV exposure: p =
0.907). Among the screening characteristics up-reported,
multivariable analysis showed that females rather than
males [OR = 0.124 95% CI: 0.021–0.558; p = 0.011] and
patients with CD4% <12.85 (median value) [OR = 0.275
95%CI: 0.077–0.875; p = 0.035 ] were less likely to har-
bour R5 virus.
Conclusion
Our study underlines the possibility for gender to influ-
ence not only the initial viral set-point as previously
shown [3], but also the probability of harbouring R5
viruses.
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